Incyte Corporation (INCY): Price and Financial Metrics


Incyte Corporation (INCY)

Today's Latest Price: $76.14 USD

1.96 (2.64%)

Updated Apr 2 1:30pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

INCY Stock Summary

  • INCY has a market capitalization of $14,617,174,258 -- more than approximately 90.88% of US stocks.
  • With a year-over-year growth in debt of 191.85%, Incyte Corp's debt growth rate surpasses 91.26% of about US stocks.
  • Over the past twelve months, INCY has reported earnings growth of 318.04%, putting it ahead of 95.94% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Incyte Corp are BGNE, STX, SWKS, CRUS, and CDNS.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to www.incyte.com.
INCY Daily Price Range
INCY 52-Week Price Range

INCY Stock Price Chart More Charts


INCY Price/Volume Stats

Current price $76.14 52-week high $96.79
Prev. close $74.18 52-week low $62.48
Day low $73.51 Volume 568,708
Day high $76.20 Avg. volume 1,922,501
50-day MA $74.54 Dividend yield N/A
200-day MA $80.82 Market Cap 16.51B

Incyte Corporation (INCY) Company Bio


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.

INCY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$76.14$755.92932%

We started the process of determining a valid price forecast for Incyte Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Incyte Corp ranked in the 84th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for INCY, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 263.42; that's higher than 96.22% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 3.19% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • INCY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 64.61% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%912%
1%922%
2%932%
3%942%
4%952%
5%963%

Want more companies with a valuation profile/forecast similar to that of Incyte Corp? See PETQ, TYHT, LCI, RHE, and STAA.


INCY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

INCY Latest Social Stream


Loading social stream, please wait...

View Full INCY Social Stream

INCY Price Returns

1-mo -2.13%
3-mo -2.26%
6-mo 1.70%
1-year -9.73%
3-year -45.03%
5-year -14.25%
YTD -12.80%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%
2015 48.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9515 seconds.